Latest news
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo has entered into a feasibility…
Iconovo Accelerator Program
On June 1st, 2023 Iconovo launched its Iconovo Accelerator to facilitate the opportunities for the company’s customers to obtain EU funding for the development…
Press releases
Feb 15, 2024, 19:35
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Feb 15, 2024, 19:35
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 15, 2024, 19:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
mfn-cus-top-disclaimer
Feb 15, 2024, 19:30
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
mfn-cus-top-disclaimer
Feb 07, 2024, 14:50
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Feb 07, 2024, 14:50
News
IR
English
Regulatory
MAR
Corporate Action
Other
Feb 06, 2024, 14:45
News
IR
English
Corporate Action
Other
Feb 06, 2024, 14:45
News
IR
Swedish
Corporate Action
Other
Feb 01, 2024, 08:00
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
mfn-cus-disclaimer
Feb 01, 2024, 08:00
News
IR
English
Regulatory
MAR
Corporate Action
Other
mfn-cus-disclaimer
Jan 08, 2024, 09:00
News
IR
English
Corporate Action
Other
Jan 08, 2024, 09:00
News
IR
Swedish
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se